Development of novel cancer treatment strategies to reduce the side effects of cisplatin

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K05757
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 37030:Chemical biology-related
• Research Institution: Fujita Health University
• Principal Investigator: Fujigaki Hidetsugu 藤田医科大学, 医療科学研究科, 准教授 (00612631)
• Co-Investigator(Kenkyū-buntansha): 山本 康子 藤田医科大学, 保健学研究科, 准教授 (00331869)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: シスプラチン / 副作用 / 腎障害

Outline of Final Research Achievements

Cisplatin is the standard chemotherapeutic agent used to treat many solid tumors. However, its metabolic byproducts are toxic to renal cells, and renal damage is a problematic side effect. Therefore, it is desirable to prevent cisplatin-induced renal toxicity without compromising its anticancer activity. Using a high-throughput screening assay, we show that a newly identified CCBL1 inhibitor, 2',4',6'-trihydroxyacetophenone, can reduce renal damage without compromising the anticancer activity of cisplatin.

Free Research Field

がん治療

Academic Significance and Societal Importance of the Research Achievements

これらの結果は、CCBL1阻害剤はシスプラチン誘発性腎障害の予防薬として使用できる可能性を示唆しており、シスプラチンをベースとしたがん治療を受けている患者のQOL向上を目指した新たな治療戦略を提供できる可能性がある。